International society of oncology pharmacy practitioners (ISOPP) position statement: The role of oncology pharmacy practitioners in immunotherapy treatment with immune checkpoint inhibitors for malignant conditions

Fecha de publicación: 01/04/2022 Fecha Ahead of Print: 01/04/2022

Autores de IIS La Fe

Asunción Albert Marí

Autor

Participantes ajenos a IIS La Fe

Walker, Andrew
Chan, Alexandre
Labra, Constanza Cortes
de Lemos, Mario L.
Geirnaert, Marc
Atik, Elif Aras
Borlagdan, Jared
Crespo, Andrea
Danilak, Melanie
Kandemir, Esin Aysel
Lim, CheaXin
Alabelewe, Ramatu Mas'ud
Mutiara, Rina
Tewthanom, Karunrat
Yim, Barbara
Nakashima, Lynne

Abstract

Oncology pharmacists, pharmacy technicians and assistants are key members of the multidisciplinary health care team (MHT) caring for patients receiving immunotherapy with immune checkpoint inhibitors. The International Society of Oncology Pharmacy Practitioners (ISOPP) developed this position statement to provide guidance on the role of oncology pharmacy practitioners in caring for patients receiving immune checkpoint inhibitors.Four key recommendations were identified: 1) participation as an integrated, collaborative member of the MHT;2) provision of education and training for patients, students, residents, fellows and other members of the MHT;3) involvement in clinical governance to optimise the use of immune checkpoint inhibitors and4) involvement in research and development in the field of immunotherapy.In summary, oncology pharmacy practitioners play essential roles within the MHT in caring for patients receiving immune checkpoint inhibitors.

Datos de la publicación

ISSN/ISSNe:: 1078-1552, 1477-092X
Tipo:: Article
Páginas:: 1065-1074
DOI:: 10.1177/10781552221090199
PubMed:: 35382638
Factor de Impacto:: 0,374 SCImago ℠
Cuartil:: Q3 SCImago ℠

Documentos

No hay documentos

Métricas

Filiaciones

Keywords

adverse events; education; immune checkpoint inhibitors; immunotherapy; oncology pharmacy; patient care; pharmacist; research; safety

Campos de Estudio

Proyectos y Estudios Clínicos

EVALUACIÓN DE EFICACIA Y TOXICIDAD DE LA TERAPIA ANTIFÚNGICA CON VORICONAZOL EN BASE A ESTUDIOS FARMACOGENÉTICOS Y ANÁLISIS FARMACOCINÉTICOS-FARMACODINÁMICOS.

Investigador Principal: VIRGINIA BOSÓ RIBELLES

MJL-VOR-2016-01 . 2018

IDENTIFICACIÓN DE FACTORES CLÍNICOS, MOLECULARES Y RADIOLÓGICOS PREDICTORES DE RESPUESTA AL TRATAMIENTO CON BEVACIZUMAB EN PACIENTES CON GLIOMAS DE ALTO GRADO: BEVA-GLIO.

Investigador Principal: ANA ALEJANDRA GARCÍA ROBLES

AGR-BEV-2018-01 . 2018

EFICACIA Y SEGURIDAD A LA QUIMIOTERAPIA INTRAPERITONEAL EN CÁNCER DE OVARIO EN ESTADIO III TRAS CIRUGÍA CITORREDUCTORA.

Investigador Principal: OCTAVIO ANTONIO BALLESTA LÓPEZ

OBL-PAC-2019-01 . 2020

Cita

Cita Bibliográfica